Pulmonary Fibrosis Biomarkers During Exacerbation
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years. In the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Admitted with an increase in respiratory symptoms
• Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA
• Age at least 18 years
Locations
Other Locations
Denmark
Herlev and Gentofte Hospital
RECRUITING
Hellerup
Time Frame
Start Date: 2020-06-13
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 50
Treatments
PFBIO-EXA
All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Gentofte, Copenhagen